 |
0 Diseases |  |
4 Trials |
|
4 Trials |  |
74 News |  |
| «12 |
- Trial initiation date: Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 26, 2016
P2, N=71, Not yet recruiting, Sponsor: University of Washington
Initiation date: Aug 2016 --> Jan 2017
- Trial initiation date: Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 28, 2016
P2, N=71, Not yet recruiting, Sponsor: University of Washington
Initiation date: Aug 2016 --> Jan 2017 Initiation date: Nov 2015 --> Aug 2016
- | bortezomib / Generic mfg., sorafenib / Generic mfg.
Enrollment open: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 14, 2016
P3, N=1750, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Nov 2015 --> Aug 2016 Suspended --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier
Clinical: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 28, 2016
P2/3, N=63, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Phase classification: P3 --> P2/3
- bortezomib / Generic mfg., sorafenib / Generic mfg.
Enrollment change, Trial suspension: AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 9, 2016
P3, N=1750, Suspended, Sponsor: National Cancer Institute (NCI)
Phase classification: P3 --> P2/3 N=1250 --> 1750 | Recruiting --> Suspended
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier
Clinical: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 29, 2015
P3, N=63, Completed, Sponsor: National Cancer Institute (NCI)
N=1250 --> 1750 | Recruiting --> Suspended Active, not recruiting --> Completed
- |||||| thioguanine / Generic mfg.
Enrollment open, Trial initiation date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Dec 15, 2015
P3, N=256, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Nov 2015
- ||||| thioguanine / Generic mfg.
Trial initiation date: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Dec 3, 2015
P3, N=256, Not yet recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting | Initiation date: Mar 2016 --> Nov 2015 Initiation date: Aug 2015 --> Mar 2016
- | New P2 trial: Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Sep 2, 2015
P2, N=71, Not yet recruiting, Sponsor: University of Washington
- |||||||||| thioguanine / Generic mfg.
New P3 trial: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (clinicaltrials.gov) - Aug 13, 2015
P3, N=256, Not yet recruiting, Sponsor: Children's Oncology Group
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier
Clinical: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 12, 2015
P3, N=63, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2015 --> Mar 2016 N=195 --> 63 | Trial primary completion date: Sep 2015 --> Dec 2014
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 2, 2015
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
N=195 --> 63 | Trial primary completion date: Sep 2015 --> Dec 2014 Suspended --> Recruiting
- Blincyto (blinatumomab) / Astellas, Amgen
P3 data: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 9, 2015
P3, N=598, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- | Blincyto (blinatumomab) / Astellas, Amgen
P3 data: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 19, 2014
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Not yet recruiting --> Recruiting | N=438 --> 598 | Initiation date: Apr 2014 --> Dec 2014
- || Leunase (L-asparaginase) / Kyowa Kirin, Kidrolase (L-asparaginase) / Jazz, Merck (MSD), Spectrila (asparaginase Escherichia coli) / Medac
Enrollment closed: AALL07P2: Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 22, 2014
P=N/A, N=59, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting | N=438 --> 598 | Initiation date: Apr 2014 --> Dec 2014 Completed --> Active, not recruiting
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier, lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Clinical: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 21, 2014
P3, N=242, Active, not recruiting, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting N=315 --> 242
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Enrollment closed: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Aug 1, 2014
P3, N=1900, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=315 --> 242 Recruiting --> Active, not recruiting
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier, lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Clinical: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jul 1, 2014
P3, N=315, Active, not recruiting, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
New P3 trial: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 31, 2014
P3, N=438, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Enrollment change: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 17, 2014
P3, N=1900, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=1580 --> 1900
- | thioguanine / Generic mfg.
Trial completion: Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) - Feb 19, 2014
P3, N=254, Completed, Sponsor: Children's Oncology Group
N=1580 --> 1900 No longer recruiting --> Completed
- ||||| Enrollment closed: Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 7, 2013
P3, N=393, Active, not recruiting, Sponsor: Children's Oncology Group
No longer recruiting --> Completed Completed --> Active, not recruiting
- ||||| thioguanine / Generic mfg.
Enrollment change: Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 25, 2013
P3, N=254, Completed, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting N=158 --> 254
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier
Clinical: Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 20, 2012
P3, N=195, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=158 --> 254 Completed --> Active, not recruiting
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen, Oncaspar liquid (pegaspargase) / Servier, lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Clinical: Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 2, 2012
P3, N=315, Recruiting, Sponsor: Children's Oncology Group
Completed --> Active, not recruiting N=244 --> 315
- Rituxan (rituximab) / Roche
Enrollment open: Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Nov 7, 2011
P2, N=77, Recruiting, Sponsor: Asan Medical Center
N=244 --> 315 Active, not recruiting --> Recruiting
- | Rituxan (rituximab) / Roche
New P2 trial: Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Sep 5, 2011
P2, N=77, Recruiting, Sponsor: Asan Medical Center